Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 in HER2+ Breast Cancer with Suboptimal Neoadjuvant Response
NCT07129187Phase 2Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan in HER2-positive breast cancer. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07129187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129187.